I think the key to getting favorable NICE pricing is the efficacy for the average patient. If the data has a lot of outlier patients that live a very long time that is great for those patients, but not for the pricing. If all the patients tend to live roughly the same amount of time after start of therapy, then NICE has a better idea of what price to accept. Variance is not your friend. Which is another reason why diagnostic markers, like meth and non-meth, are important; it lets the NICE price the therapy differentially to allow the patients most likely to benefit to obtain the drug. Nobody likes to think about patients not getting access for economic reasons, but that will increasingly be the reality going forward. Those are not easy decisions to make.